Literature DB >> 11438462

Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.

D Giri1, M Ittmann.   

Abstract

Benign prostatic hyperplasia (BPH) is an extremely common disease of older men in which there is benign overgrowth of the prostatic transition zone, leading to obstruction of urine outflow. Fibroblast growth factor (FGF) 2, a potent growth factor for prostatic stromal and epithelial cells, is increased twofold in BPH and its concentration is correlated with stromal proliferation in this condition. Immunohistochemistry of normal and hyperplastic prostate revealed that FGF2-expressing stromal cells were present in higher numbers near the epithelial acini, implying that epithelial cells may express a factor that induces FGF2 expression by stromal cells. Conditioned medium from primary cultures of prostatic epithelial cells was capable of inducing increased expression of FGF2 by primary stromal cultures. Blocking experiments with neutralizing anti-interleukin (IL)-8 antibodies and pretreatment with lipopolysaccharide, which down-regulates the IL-8 receptor, show that this inducing activity is because of the presence of IL-8 in the epithelial-conditioned medium. Analysis of normal prostatic peripheral zone and BPH tissue by enzyme-linked immunosorbent assay reveals that IL-8 is present at increased levels in hyperplastic prostate. Therefore IL-8 produced by prostatic epithelial cells can induce FGF2, a potent stromal and epithelial growth factor, and in this manner promote the abnormal proliferation of the prostatic transition zone that is critical in the pathogenesis of BPH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438462      PMCID: PMC1850405          DOI: 10.1016/S0002-9440(10)61681-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Acidic fibroblast growth factor mRNA is expressed by cardiac myocytes in culture and the protein is localized to the extracellular matrix.

Authors:  H L Weiner; J L Swain
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Asymptomatic inflammation and/or infection in benign prostatic hyperplasia.

Authors:  J C Nickel; J Downey; I Young; S Boag
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

3.  Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia.

Authors:  H Mori; M Maki; K Oishi; M Jaye; K Igarashi; O Yoshida; M Hatanaka
Journal:  Prostate       Date:  1990       Impact factor: 4.104

4.  Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation.

Authors:  C Kevil; P Carter; B Hu; A DeBenedetti
Journal:  Oncogene       Date:  1995-12-07       Impact factor: 9.867

5.  Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia.

Authors:  D Giri; M Ittmann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

6.  alpha1-Adrenergic stimulation of FGF-2 promoter in cardiac myocytes and in adult transgenic mouse hearts.

Authors:  K A Detillieux; J T Meij; E Kardami; P A Cattini
Journal:  Am J Physiol       Date:  1999-03

7.  Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate.

Authors:  E R Sherwood; C J Fong; C Lee; J M Kozlowski
Journal:  Endocrinology       Date:  1992-05       Impact factor: 4.736

8.  Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates.

Authors:  F P Begun; M T Story; K A Hopp; E Shapiro; R K Lawson
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

9.  The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study.

Authors:  R J Glynn; E W Campion; G R Bouchard; J E Silbert
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897

10.  Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes.

Authors:  A R Lloyd; A Biragyn; J A Johnston; D D Taub; L Xu; D Michiel; H Sprenger; J J Oppenheim; D J Kelvin
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

View more
  53 in total

1.  The picture of the prostatic lymphokine network is becoming increasingly complex.

Authors:  Georg E Steiner; Bob Djavan; Gero Kramer; Alessandra Handisurya; Martin Newman; Chung Lee; Michael Marberger
Journal:  Rev Urol       Date:  2002

Review 2.  What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype?

Authors:  Carl W White; Edilson Dantas da Silva Junior; Linzi Lim; Sabatino Ventura
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

3.  Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells.

Authors:  Kai Wang; Linfeng Cheng; Yinghong Liang; Donghui Liu; Kai Li; Ping Wang
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

4.  Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Authors:  Opal Lin-Tsai; Peter E Clark; Nicole L Miller; Jay H Fowke; Omar Hameed; Simon W Hayward; Douglas W Strand
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

5.  -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race.

Authors:  S Mandal; F Abebe; J Chaudhary
Journal:  Genet Mol Res       Date:  2014-01-10

Review 6.  Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.

Authors:  LaTayia Aaron; Omar E Franco; Simon W Hayward
Journal:  Urol Clin North Am       Date:  2016-08       Impact factor: 2.241

7.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  The senescence-associated secretory phenotype promotes benign prostatic hyperplasia.

Authors:  Paz Vital; Patricia Castro; Susan Tsang; Michael Ittmann
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

9.  A signaling network in phenylephrine-induced benign prostatic hyperplasia.

Authors:  Jayoung Kim; Yutaka Yanagihara; Tadahiko Kikugawa; Mihee Ji; Nozomu Tanji; Yokoyama Masayoshi; Michael R Freeman
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

Review 10.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.